Facing the Challenges in Vaccine Upstream Bioprocessing - 12

Facing the Challenges in Vaccine Upstream Bioprocessing * Scalable Production of AAV Vectors

Table. Method of removal and measurement of AAV vector production impurities
AAV Vector Production
Impurity

Method of Removal

Method of Measurement

Residual host cell DNA/RNA
(nuclease-sensitive)

Nuclease treatment
(Benzonase)

qPCR using amplicons to generic host cell genome
(e.g., 18SRNA gene); qPCR using amplicons for
sequences of specific concern (e.g., AdE1); qPCR
using amplicons for non-vector genome sequences

Residual host cell protein

Ultracentrifugation; ion
exchange chromatography

ELISA using polyclonal antibodies detecting representative proteins

Residual plasmid DNA
(nuclease-sensitive)

Ultracentrifugation;
ion exchange
chromatography

qPCR using amplicons for helper virus sequences;
infectious titer of helper viruses; ELISA or Western
blotting for helper virus proteins

Residual helper viruses
(nucleic acids and proteins)

Nuclease treatment
(Benzonase)

Various, depending on component

AAV empty capsids

Ultracentrifugation;
ion exchange
chromatography

Electron microscopy; spectrophotometry

Encapsidated host
cell nucleic acids
(nuclease-resistant)

qPCR using amplicons to generic host cell genome
sequences

Table continued on page 15

12

| GENengnews.com

Figure 1. Elements in optimization.
Before optimization, the trans-splicing
efficiency is about 1-5% when compared
to GFP expression from single vector.
After optimization, the efficiency reaches
about 25-50%.


http://www.GENengnews.com

Facing the Challenges in Vaccine Upstream Bioprocessing

Table of Contents for the Digital Edition of Facing the Challenges in Vaccine Upstream Bioprocessing

Contents
Facing the Challenges in Vaccine Upstream Bioprocessing - 1
Facing the Challenges in Vaccine Upstream Bioprocessing - 2
Facing the Challenges in Vaccine Upstream Bioprocessing - 3
Facing the Challenges in Vaccine Upstream Bioprocessing - Contents
Facing the Challenges in Vaccine Upstream Bioprocessing - 5
Facing the Challenges in Vaccine Upstream Bioprocessing - 6
Facing the Challenges in Vaccine Upstream Bioprocessing - 7
Facing the Challenges in Vaccine Upstream Bioprocessing - 8
Facing the Challenges in Vaccine Upstream Bioprocessing - 9
Facing the Challenges in Vaccine Upstream Bioprocessing - 10
Facing the Challenges in Vaccine Upstream Bioprocessing - 11
Facing the Challenges in Vaccine Upstream Bioprocessing - 12
Facing the Challenges in Vaccine Upstream Bioprocessing - 13
Facing the Challenges in Vaccine Upstream Bioprocessing - 14
Facing the Challenges in Vaccine Upstream Bioprocessing - 15
Facing the Challenges in Vaccine Upstream Bioprocessing - 16
Facing the Challenges in Vaccine Upstream Bioprocessing - 17
Facing the Challenges in Vaccine Upstream Bioprocessing - 18
Facing the Challenges in Vaccine Upstream Bioprocessing - 19
Facing the Challenges in Vaccine Upstream Bioprocessing - 20
Facing the Challenges in Vaccine Upstream Bioprocessing - 21
Facing the Challenges in Vaccine Upstream Bioprocessing - 22
Facing the Challenges in Vaccine Upstream Bioprocessing - 23
Facing the Challenges in Vaccine Upstream Bioprocessing - 24
Facing the Challenges in Vaccine Upstream Bioprocessing - 25
Facing the Challenges in Vaccine Upstream Bioprocessing - 26
Facing the Challenges in Vaccine Upstream Bioprocessing - 27
Facing the Challenges in Vaccine Upstream Bioprocessing - 28
Facing the Challenges in Vaccine Upstream Bioprocessing - 29
Facing the Challenges in Vaccine Upstream Bioprocessing - 30
Facing the Challenges in Vaccine Upstream Bioprocessing - 31
Facing the Challenges in Vaccine Upstream Bioprocessing - 32
Facing the Challenges in Vaccine Upstream Bioprocessing - 33
Facing the Challenges in Vaccine Upstream Bioprocessing - 34
Facing the Challenges in Vaccine Upstream Bioprocessing - 35
https://www.nxtbookmedia.com